Schmitt-Egenolf Marcus
Department of Public Health and Clinical Medicine, Dermatology and Venereology, Umeå University, Umeå, Sweden.
Dermatology. 2007;214(2):112-7. doi: 10.1159/000098568.
With the introduction of new systemic drugs for the management of psoriasis, we felt an obligation in Sweden to establish a trusted tool to monitor their use. We formed PsoReg to create a solid, long-term database in order to analyze safety and effectiveness of different systemic psoriasis treatment regimens. PsoReg will provide information to help clinicians individualize therapy on a rational basis through evaluation of effectiveness and adverse effects in specific patient subgroups. Designed and managed by specialized health care professionals, PsoReg will enroll all psoriasis patients on systemic treatment to allow a fair comparison of old versus new-generation psoriasis treatments. PsoReg will even create benchmark data for quality assurance of the medical service. A web-based design allows real-time pharmacovigilance and enables the registry to assist clinicians in their day-to-day management of psoriasis patients. In this way PsoReg can become an integrated part of tomorrow's dermatology.
随着用于银屑病治疗的新型全身性药物的引入，我们瑞典人觉得有义务建立一个可靠的工具来监测这些药物的使用情况。我们成立了银屑病登记处（PsoReg），以创建一个坚实的长期数据库，以便分析不同全身性银屑病治疗方案的安全性和有效性。PsoReg将提供信息，通过评估特定患者亚组的有效性和不良反应，帮助临床医生在合理的基础上实现个体化治疗。由专业医疗保健人员设计和管理，PsoReg将纳入所有接受全身性治疗的银屑病患者，以便对新一代与旧一代银屑病治疗进行公平比较。PsoReg甚至将为医疗服务的质量保证创建基准数据。基于网络的设计允许进行实时药物警戒，并使该登记处能够协助临床医生日常管理银屑病患者。通过这种方式，PsoReg可以成为未来皮肤病学的一个组成部分。
